相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented
Dominique Farge et al.
CANCERS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer-Associated Venous Thromboembolism in the Real World - From the COMMAND VTE Registry -
Jiro Sakamoto et al.
CIRCULATION JOURNAL (2019)
Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
Helen Strongman et al.
LANCET (2019)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2019)
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Corinne Frere et al.
CANCERS (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry
Corinne Frere et al.
THROMBOSIS AND HAEMOSTASIS (2018)
The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
Isabelle Mahe et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
C. Kearon et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Gary E. Raskob et al.
LANCET HAEMATOLOGY (2016)
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial
Agnes Y. Y. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
G. Agnelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
Martin H. Prins et al.
LANCET HAEMATOLOGY (2014)
Epidemiology of cancer-associated venous thrombosis
Jasmijn F. Timp et al.
BLOOD (2013)
Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States
Alok A. Khorana et al.
CANCER (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D. Hull et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
Steven R. Deitcher et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2006)
Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
Julia Bohlius et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer - A randomized controlled study
G Meyer et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
分享论文
